Biden wishes to spend billions more on COVID-19 efforts at home and abroad. US federal funding agencies haven’t discussed specific funding opportunities based on the administration’s proposals, but it is likely there will be more funding available to biotech R&D on anti-virals, vaccines, diagnostics, etc.
Tag Archive for: NIH
Dr. William Bozza discusses non-dilutive funding opportunities at NCI and NIH.
Dr. Charles L. Cywin discusses non-dilutive funding opportunities at NINDS and NIH.
Dr. Daniel Gossett discusses non-dilutive funding opportunities at NIDDK and NIH.
Dr. Natalia Kruchinin discusses non-dilutive funding opportunities at NIAID and NIH.
The National Institute of Allergy & Infectious Diseases (NIAID) has just published a Broad Agency Announcement (BAA). This BAA contains four distinct Research Areas: Vaccines, Therapeutics, and In-Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections and Emerging Infectious Diseases, and Antivirals for Specific RNA Viral Families of Pandemic Potential.
FreeMind can help you apply for these funds or for other non-dilutive grants and contracts. FreeMind will host a webinar about the BAA on February 7, at 1:00 PM EST.
Website Links
Address
FreeMind Group
6 Liberty Square #2783
Boston, MA 02109